Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.48 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.48 |
| ▸ | FABP1 | P07148 | 7/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20178809 | 0.90 | NR1H4 (0.48) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL20119040 | 0.86 | NR1H4 (0.49) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL20119181 | 0.85 | NR1H4 (0.55) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL20178897 | 0.79 | NR1H4 (0.43) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL20178877 | 0.77 | NR1H4 (0.53) | NR1H4HSD17B13 | |
| SCHEMBL20178908 | 0.76 | NR1H4 (0.58) | NR1H4 | |
| SCHEMBL20173899 | 0.76 | NR1H4 (0.61) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL20119263 | 0.74 | NR1H4 (0.57) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL20119013 | 0.74 | NR1H4 (0.57) | NR1H4HSD17B13FABP1FABP4 | |
| SCHEMBL20178998 | 0.74 | NR1H4 (0.48) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885HSD17B13 500/4885FABP1 45/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885HSD17B13 500/4885FABP1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.